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BACKGROUND: Inflammation may underlie cancer-related fatigue; however, there are no studies that assess the relation between fa-
tigue and cytokines in patients with advanced disease versus patients without disease activity. Furthermore, the relation between
cytokines and the separate dimensions of fatigue is unknown. Here, association of plasma levels of inflammatory markers with physi-
cal fatigue and mental fatigue was explored in advanced cancer patients and cancer survivors. METHODS: A total of 45 advanced
cancer patients and 47 cancer survivors completed the subscales Physical Fatigue and Mental Fatigue of the Multidimensional Fa-
tigue Inventory. Plasma concentrations of C-reactive protein (CRP), interleukin-1 receptor antagonist (IL-1-ra), interleukin-6 (IL-6),
interleukin-8 (IL-8), and neopterin were measured. Nonparametric tests were used to assess differences in fatigue intensity and levels
of inflammatory markers and to determine correlation coefficients between the fatigue dimensions and inflammatory markers.
RESULTS: Compared with cancer survivors, patients with advanced cancer had higher levels of physical fatigue (median 16 vs 9, P <
.001) and mental fatigue (median 11 vs 6, P ¼ .01). They also had higher levels of all cytokines (P < .01). In advanced cancer, CRP (r ¼
0.49, P ¼ .001), IL-6 (r ¼ 0.43, P ¼ .003), IL-1-ra (r ¼ 0.32, P ¼ .03), and neopterin (r ¼ 0.25, P ¼ .10) were correlated with physical but
not with mental fatigue. In cancer survivors, only IL-1-ra was related to both physical fatigue (r ¼ 0.24, P ¼ .10) and mental fatigue (r
¼ 0.35, P ¼ .02). CONCLUSIONS: In advanced cancer, inflammation seems to be associated with physical fatigue, but not to mental
fatigue. In cancer survivors, there was no convincing evidence that inflammation plays a major role in fatigue. Cancer 2012;118:6005-
6011.VC 2012 American Cancer Society.
KEYWORDS: neoplasms, fatigue, mental fatigue, survivors, palliative care, C-reactive protein, interleukin-6, interleukin-8, interleukin-1
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Fatigue is one of the most frequent and pervasive symptoms among cancer patients. Patients in all stages of the disease tra-
jectory, from before diagnosis to years after treatment, experience fatigue, which has a greater negative impact on quality
of life and daily functioning than any other cancer-related symptom.1 Patients describe their feelings of fatigue as physical,
cognitive, and affective senses of tiredness, which indicates that fatigue is a multidimensional phenomenon.2
Although the exact pathogenesis of fatigue is still unknown, there is not much doubt about the multicausality of
fatigue.3 Inflammation has been hypothesized to be one of the causes of cancer-related fatigue.3-6 In a review that pooled
correlation coefficients between fatigue and cytokine serum levels of individual studies, a statistically significant positive
association was found between fatigue and circulating levels of interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-
1-ra), and neopterin.5 These inflammatory markers may be produced by tumor cells or by inflammatory cells after their
stimulation by antitumor treatment, tumor cells or psychological distress.6 They may provoke cancer-related fatigue by
inducing anemia, disturbances in the hypothalamic-pituitary-adrenal axis or alterations in brain serotonin metabolism.4
Although a statistically significant association between inflammation and fatigue has been found in cancer patients
at various stages of the disease trajectory,5 there are no studies that compared different groups of patients, ie, patients with
advanced disease and cancer survivors, with respect to this association. Nevertheless, because tumor load, antitumor
therapy, and distress are known to affect cytokine levels,6 it seems reasonable to suppose a different role of inflammation
at various time points along the disease trajectory. Furthermore, most studies on cytokines and fatigue measured fatigue as
a single symptom, whereas fatigue is known to have both physical and cognitive dimensions. These dimensions of fatigue
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might have different etiologies. For that reason, it is im-
portant to investigate whether inflammation is associated
with all dimensions of fatigue or only with a single
dimension.
In contrast to previous studies, we explored the asso-
ciation between fatigue and inflammation in patients with
advanced cancer and in cancer survivors and for the physi-
cal and mental dimensions of fatigue separately. Based on
the review of Schubert et al, we decided to measure plasma
concentrations of IL-6, IL-1-ra, and neopterin, because
these markers were found to be significantly correlated
with fatigue.5 Furthermore, we measured C-reactive pro-
tein (CRP), because it is considered to be a surrogate
marker of IL-6 activity4 for which routine measurements
are available in clinical practice. We also measured inter-
leukin-8 (IL-8), because we previously found an increase
in the concentration of this cytokine after infusion of tax-
anes, which are known to cause major fatigue (unpub-
lished data). In these exploratory analyses, we aimed to
identify inflammatory markers possibly involved in the
pathogenesis of cancer-related fatigue, which should be
studied in greater detail in subsequent studies. Therefore,
we determined in both advanced cancer patients and can-
cer survivors: 1) which inflammatory markers are related
to physical fatigue and mental fatigue, and 2) whether
inflammatory markers that are associated with fatigue are
related to each other.
MATERIALS AND METHODS
Study Population
Patients included in this study originated from an obser-
vational study on differences in fatigue experiences
between advanced cancer patients and cancer survivors.7
Advanced cancer patients admitted to the palliative care
unit or having an appointment at the outpatient clinic of
the Erasmus MC Daniel den Hoed Cancer Centre, Rot-
terdam, the Netherlands, were invited to participate in the
study. They were eligible when systemic anticancer ther-
apy was no longer available and when they had not
received any systemic anticancer therapy in the last 4
weeks.
For every advanced cancer patient, a cancer survivor
matched for age, sex, and cancer diagnosis was recruited at
the outpatient clinic. If feasible, they were also matched
for treatment received for the primary tumor. These can-
cer survivors were eligible if their last treatment had been
received 1 to 5 years ago and if there was no evidence of
disease at the moment of inclusion. Patients still receiving
adjuvant endocrine therapy for breast cancer were eligible
for inclusion.
Patients for whom regular laboratory examinations
were planned by their physician were asked permission for
taking 1 extra blood sample for research on the relation-
ship between fatigue and inflammatory markers. Here,
data are published for the patients who both provided a
blood sample and completed the fatigue questionnaire.
The Research Ethics Committee at the Erasmus
MC granted ethical permission for this study, and all par-
ticipants gave informed consent before data collection.
Procedures
All eligible participants were given oral and written infor-
mation by the first author and were asked to give written
consent. Venous blood samples, anticoagulated with
ethylene diamine tetraacetic acid, were taken between
8AM and 12noon in order to minimize the effects of diur-
nal fluctuations in cytokine levels.8 Plasma was harvested
within 2 hours from collection, and stored in aliquots at
80C until analysis. Patients were requested to complete
the fatigue questionnaire on the same day as the labora-
tory examination.
Questionnaire
Data on demographic characteristics and disease charac-
teristics, including tumor type and anticancer therapy
received, were collected from the electronic medical
record.
The dimensions of fatigue were measured with the
physical fatigue and mental fatigue subscales of the Multi-
dimensional Fatigue Inventory (MFI). The subscale phys-
ical fatigue consists of 4 statements referring to the
physical sensations related to subjective fatigue, and the
subscale mental fatigue consists of 4 statements referring
to cognitive symptoms (Table 1). Patients have to indicate
to what extent each statement applied to them on a 5-
point Likert scale. Both subscale scores range from 4 to
20, with higher score indicating more severe fatigue.9
Schwarz et al provided reference values for theMFI, deter-
mined in a sample of 2037 German representatives from
the general population.10
Measurement of Inflammatory Markers
Plasma concentrations of CRP, IL-1-ra, and neopterin
were measured by enzyme-linked immunosorbent assays
using commercially available kits (CRP: Assay Pro, St
Charles, Mo; IL-1-ra: R&D Systems, Minneapolis,
Minn; neopterin: IBL International, Hamburg, Germany)
according to manufacturer instructions. IL-6 and IL-8
plasma concentrations were determined by the Cytomet-
ric Bead Arrays (BD Bioscience, San Diego, Calif) accord-
ing to the manufacturer instructions. Samples were tested
in duplicate and related to the standard curves for
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each assay. The lowest detection limit per assay was 0.25
ng/mL for CRP; 1.35 nmol/L for neopterin; 15.6 pg/mL
for IL-1-ra; 5.0 pg/mL for IL-6; and 2.5 pg/mL for IL-8.
If the level of an inflammatory marker was undetectable,
the detection limit for that cytokine was imputed in the
data set.
Data Analyses
Because this study is a secondary analysis of a previous
study, we did not perform a power analysis. Because of the
explorative character of this study, P values were not cor-
rected for multiple testing and associations with P < 0.10
are considered to be important to investigate in further
research. Differences in patients’ and disease characteris-
tics between advanced cancer patients and cancer survi-
vors were assessed with the chi-square test. Differences
between advanced cancer patients and cancer survivors in
the intensity of fatigue and the levels of the inflammatory
markers were determined with the Mann-Whitney U test.
For both advanced cancer patients and cancer survivors,
Spearman correlation coefficients were calculated to
explore the relationships between fatigue measurements
and concentrations of inflammatory markers.
RESULTS
We included a total of 63 advanced cancer patients and
63 cancer survivors in the original study between October
2008 and October 2010. Eighteen advanced cancer
patients and 16 cancer survivors did not provide a blood
sample, because their physician had not planned a regular
laboratory examination. In this study, we present the data
of the 45 advanced cancer patients and the 47 cancer sur-
vivors who both completed the questionnaire and pro-
vided a blood sample. In this analysis, 12 advanced cancer
patients and 14 cancer survivors were unmatched because
their match did not provide a blood sample, 22 pairs of
patients were matched for age, sex, and diagnosis, and 11
pairs of patients were matched for age, sex, diagnosis, and
treatment of primary tumor. Patient characteristics and
fatigue scores are presented in Table 2. There were no
significant differences between the groups in age, sex, or
tumor diagnosis. Advanced cancer patients had a signifi-
cantly lower physical performance than cancer survivors
(P < .01). Advanced cancer patients had undergone pri-
mary surgery less frequently than cancer survivors (P <
.01), because 18% of advanced cancer patients already
had advanced disease at the time of diagnosis. Advanced
cancer patients had been treated with chemotherapy and
radiotherapy more frequently than cancer survivors (P <
.05). Compared to cancer survivors, advanced cancer
patients had higher levels of physical fatigue (median,
16 vs 9, P < .001) and mental fatigue (median 11 vs 6,
P¼ .01).
Levels of inflammatory markers for advanced cancer
patients and cancer survivors are shown in Figure 1. Levels
of all inflammatory markers were higher in advanced can-
cer patients than in cancer survivors (P < .01). A total of
93% of advanced cancer patients and 21% of cancer survi-
vors had at least 1 marker above the upper limit of the nor-
mal range (P < .001). Seventy-three percent of advanced
cancer patients and 6% of cancer survivors had at least
1 marker at 2 times higher than the upper limit of the
normal range (P< .001).
The relationships between fatigue measurements
and levels of inflammatory markers for both advanced
cancer patients and cancer survivors are shown in Figure
2. In the advanced cancer patients, physical fatigue was
positively correlated with the levels of CRP (r¼ 0.49, P¼
.001), IL-6 (r ¼ 0.43, P ¼ .003), IL-1-ra (r ¼ 0.32, P ¼
.03), and, to a lesser extent, neopterin (r¼ 0.25, P¼ .10).
No inflammatory markers were related to mental fatigue
in the advanced cancer patients. In the cancer survivors,
IL-1-ra was related to both physical fatigue (r¼ 0.24, P¼
.10) and mental fatigue (r¼ 0.35, P¼ .02). In this group,
no associations were found for any other soluble factors
assessed with either physical or mental fatigue.
All inflammatory markers that were associated with
physical fatigue in the advanced cancer patients were posi-
tively correlated with each other as detailed in Table 3.
DISCUSSION
In this study, we explored whether fatigue dimensions
were associated with inflammatory markers in different
Table 1. Items of the Subscales Physical Fatigue and Mental Fatigue of the Multidimensional
Fatigue Inventory9
Physical Fatigue Mental Fatigue
1. Physically I feel only able to do a little 1. When I am doing something, I can keep my thoughts on it
2. Physically I can take on a lot 2. I can concentrate well
3. Physically I feel I am in a bad condition 3. It takes a lot of effort to concentrate on things
4. Physically I feel I am in an excellent condition 4. My thoughts easily wander
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groups of cancer patients. In the advanced cancer patients,
CRP, IL-6, IL-1-ra, and neopterin were significantly asso-
ciated with physical fatigue but not with mental fatigue.
These findings suggest that physical fatigue and mental
fatigue have different underlying pathogeneses in these
patients. On the contrary, in the cancer survivors, both
physical fatigue and mental fatigue were associated with
IL-1-ra only, which indicates that the pathogenesis of
physical and mental fatigue might differ between
advanced cancer patients and cancer survivors.
Four other studies have previously investigated the
relation between at least 1 of these inflammatory markers
and fatigue in advanced cancer patients.11-14 The only
study that measured fatigue multidimensionally in termi-
nally ill advanced cancer patients also found the IL-6 con-
centrations to be related to physical fatigue and not to
mental fatigue.11 The 3 other studies measured fatigue as
1 symptom (unidimensionally), and their results were in
contrast with our findings.12-14 Two of these studies
investigated the relation between IL-6 and fatigue in
advanced cancer patients and could not find a significant
relation.13,14 However, these patients had a better per-
formance than our patients (93%14 and 75%13 Eastern
Cooperative Oncology Group performance status
[ECOG PS]  1 vs 38% ECOG PS  1 in our study).
Therefore, our patients were more vulnerable and might
have experienced more fatigue. The third study investi-
gated the relation between CRP and symptom clusters in
patients with advanced cancer of the lung or pancreas.
Fatigued patients had similar CRP concentrations as non-
fatigued patients. Furthermore, in this study, hardly any
patient had a CRP concentration above the upper limit of
the normal range (10 lg/mL).12 No studies assessing the
relationship between fatigue and IL-1-ra, IL-8, or neo-
pterin in advanced cancer patients have been published
thus far.
In the advanced cancer patients, all inflammatory
markers that were associated with physical fatigue were






(n 5 45) (n 5 47)
N (%) N (%)
Age, y (mean, range) 58 (22-81) 57 (36-77)
Sex
Male 18 (40%) 19 (40%)
Female 27 (60%) 28 (60%)
WHO performancea
0 1 (2%) 29 (62%)
1 16 (36%) 17 (36%)




Breast 15 (33%) 15 (32%)
Gastrointestinal 11 (24%) 14 (30%)
Urogenital 9 (20%) 8 (17%)
Other 10 (22%) 10 (21%)
Treatment received
Surgery
Total 33 (73%) 46 (98%)a
Curative 32 (71%) 46 (98%)a
Palliative 11 (24%)
Chemotherapy
Total 37 (82%) 30 (64%)b
Curative 17 (38%) 30 (64%)b
Palliative 31 (69%)
Radiotherapy
Total 33 (73%) 24 (51%)b
Curative 19 (42%) 24 (51%)
Palliative 22 (49%)
Hormonal therapy
Total 13 (29%) 14 (30%)
Curative 6 (13%) 14 (30%)
Palliative 12 (27%)
Months since last treatment
(median, IQR)c
2.5 (1.0-7.0) 28.0 (20.0-47.0)
Fatigue scores (median, IQR)
Physical fatigue 16 (13-19) 9 (5-12)b
Mental fatigue 11 (6-15) 6 (4-12)b
IQR indicates interquartile range; WHO, World Health Organization.
aP < 0.01
bP < 0.05
c Surgery, chemotherapy, or radiotherapy.
Figure 1. Box plot of plasma concentrations of C-reactive
protein (CRP), interleukin-6 (IL-6), interleukin-1 receptor
antagonist (IL-1-ra), interleukin-8 (IL-8), and neopterin in
advanced cancer patients (ACP) and cancer survivors (CS).
Horizontal line indicates median; box is interquartile range;
whiskers indicate range (without outliers); dots indicate out-
liers (>1.5 times interquartile range above 75th or below 25th
percentile).
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positively intercorrelated. CRP is an acute-phase protein
produced by hepatocytes after stimulation by IL-6, which
is reflected by a strong correlation between CRP and IL-6
in our study.15 IL-6 production is stimulated by IL-1b.16
Both IL-1b and IL-6 stimulate the production of IL-1-ra,
an anti-inflammatory cytokine that antagonizes IL-1 ac-
tivity.17 Therefore, of the markers that were correlated
with fatigue in our study, IL-6 in particular might play an
important role in the fatigue-inducing cytokine cascade.
Subsequently, the elevated levels of both CRP and IL-1-ra
in this study could be caused by increased IL-6 activity.
Interestingly, in the treatment of IL-6–mediated Castle-
man’s disease, both blockade of IL-6 production by IL-1-
ra administration18 and blockade of IL-6 activity by
administration of anti–IL-6 antibodies19 were highly
effective in decreasing disease activity and in alleviating fa-
tigue. Furthermore, there are some data from phase 1 and
phase 2 clinical trials which suggest that anti–IL-6 anti-
body treatment in patients with advanced lung cancer
might alleviate fatigue.20
The association between inflammatory markers and
fatigue in cancer survivors was investigated previously in 6
studies.21-26 In the only study that measured fatigue mul-
tidimensionally, IL-1-ra was associated with physical fa-
tigue but not with mental fatigue, whereas we found an
association with both physical and mental fatigue. Fur-
thermore, this study found a significant correlation
between CRP and physical fatigue, whereas we did not.25
The 5 other studies in cancer survivors measured fatigue
Figure 2. Scatter plots of the fatigue scores and plasma concentrations of inflammatory markers, including C-reactive protein
(CRP), interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-1-ra), interleukin-8 (IL-8), and neopterin, of individual patients. The
Spearman correlation coefficient is presented for significant correlations.
Table 3. Spearman Correlations Between Inflammatory
Markers Significantly Associated With Physical Fatigue in
Advanced Cancer Patients
IL-6 IL-1-ra Neopterin
C-Reactive protein 0.82a 0.50a 0.35b
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only unidimensionally.21-24,26 In a study on breast cancer
survivors, CRP was associated with fatigue, in contrast to
our results.26 Similar to our results, there was no relation
between IL-6 and fatigue in other studies on cancer survi-
vors.22-26 The results of the studies on IL-1-ra and fatigue
and on neopterin and fatigue in cancer survivors were
contradictory. Some studies found an association between
fatigue and IL-1-ra21,22 or neopterin,23,25,26 whereas
other studies did not find an association between fatigue
and IL-1-ra23,26 or neopterin.21 The association between
IL-8 and fatigue has never been studied before in cancer
survivors.
The clinical meaning of the solitary association of
IL-1-ra and fatigue in the cancer survivors remains
unclear. Because this relation is congruent with the litera-
ture,21,22,25 it seems unlikely that the statistically signifi-
cant correlation we found is caused by chance, because of
multiple testing. On the other hand, if inflammation is
one of the important causes of fatigue in the cancer survi-
vors, we would have expected more inflammatory markers
to be related to fatigue, because they are not independent
factors, but part of complex, collaborating pathways.
There are several limitations to this study, hindering
the interpretation of the results. Because of the cross-sec-
tional study design, we were not able to prove causality
between inflammation and physical fatigue. Longitudinal
measurements of both fatigue severity and concentrations
of inflammatory markers are needed to confirm the causal
relationship between them. Furthermore, despite our
matching advanced cancer patients and cancer survivors
to minimize intergroup heterogeneity, there is a great
intragroup variability in age, diagnosis, and intensity of
treatment. Finally, in this explorative study, we did not
control for other variables that are known to influence
fatigue, such as depression. Depression has been reported
to be correlated with both physical and mental fatigue in
patients with advanced cancer27 as well as cancer survi-
vors.28 Also, behavioral symptoms such as depression
have been hypothesized to be related to cytokine release.29
However, a recent study in breast cancer patients who
completed curative chemotherapy recently failed to find a
correlation between depression and inflammatory activity;
whereas unidimensionally measured fatigue was corre-
lated with both inflammation and depression.30 These
results further substantiate the multicausality of cancer-
related fatigue and the need for large, prospective studies
to unravel the etiologic mechanisms.
Nevertheless, the novelty of this study lies in the
simultaneous measurement of the relation between
inflammation and fatigue dimensions in different groups
of cancer patients. We showed that inflammation seems
to be associated with physical fatigue, but not to mental
fatigue in the advanced cancer patients, whereas there
were no strong indications that inflammation plays a
major role in cancer survivors’ fatigue. In future research,
longitudinal studies controlling for important confound-
ers are needed to prove the causal relationship between
inflammation and fatigue. Furthermore, if it should be
proven that cytokines cause fatigue, it has to be investi-
gated which pathogenetic pathways lead from elevated
concentrations of inflammatory markers in plasma to sub-
jective complaints of fatigue. Hopefully, the identification
of the important inducers of cancer-related fatigue will
finally lead to novel targets of treatment, for example by
blockade of IL-6 production or IL-6 activity.
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